Choice utility values (with class and cost attributes) derived for HCPs in US, Europe, and Japan. A positive choice utility value for a given attribute level indicates a more desirable attribute, whereas a negative utility value of the attribute level indicates a less desirable attribute. For each attribute, the larger the spread from the highest to lowest utility values, the higher that attribute's importance. Of the 13 attributes, the importance of each attribute has been ranked for each country/region. EU, Europe; ICS, inhaled corticosteroids; JP, Japan; LABA, long-acting β agonist; LAMA, long-acting muscarinic antagonist; US, United States.